Levacetylleucine CAS# 1188-21-2 N-乙酰-L-亮氨酸

Levacetylleucine (N-acetyl-L-leucine, NALL) has demonstrated both cellular and animal bioactivity consistent with neuroprotective and lysosome-modulating effects. In vitro, NALL induces nuclear translocation and activation of TFEB, a master regulator of lysosomal biogenesis and autophagy, leading to increased expression of TFEB target genes such as LAMP1 at clinically relevant concentrations—effects not observed with L-leucine or the D-enantiomer. In vivo, NALL treatment in Npc1-/- mice (a Niemann-Pick disease type C model) reduced glycosphingolipid accumulation (e.g., GM1a, GM2, GA2) in forebrain and cerebellum, decreased cerebellar neuroinflammation (CD68-positive microglia), improved motor coordination, and modestly extended survival when administered pre-symptomatically. Additional studies in rats and mice reported improved postural recovery after labyrinthectomy (60 mg/kg IV for 15 days) and reduced cortical neuronal loss after traumatic brain injury (100 mg/kg PO daily for 28 days).